US and UK Conclude Duty-Free Agreement on Prescription Drugs.

Britain and America have announced a major trade agreement that will maintain zero levies on UK drug exports entering the American market.

The Terms of the Deal

Under the terms of the agreement, the UK has pledged to raise funding on medicines through the NHS. This commitment secures that tariffs on these vital exports will remain at zero for a period of the next three years.

This development is in response to recent warnings to significantly raise import taxes on patented pharmaceutical imports, with figures floated as high as one hundred percent.

"This deal between the UK strengthens the global environment for new treatments and introduces much-needed equity to transatlantic pharmaceutical trade," a statement declared.

Trade Importance

Pharmaceuticals are one of the Britain's biggest export categories to the United States, which is by far the biggest destination for large companies like GSK and AstraZeneca.

Statistics show that in the one-year period prior to last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount represented a significant portion of all goods exports in that period.

"This deal secures jobs, boosts investment and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary remarked.

Specific British Pledges

The pact includes several specific changes from the British government:

• Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be unaffordable by a quarter.
• Increased NHS Spending: There is a aim to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
• Payback Limit: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds exceeded twenty percent.

Industry Background

The pact follows a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.

These tensions were heightened by assertions that US customers were paying a premium for the same drugs than patients in the Britain and the EU.

In recent months, several significant drug company projects in the UK have been delayed or abandoned, while substantial investments have been announced toward projects in the United States.

One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a percentage of its resources over the previous ten-year period.